Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq: NBIX) scheduled its Q1 2026 financial results release and conference call for May 5, 2026. The press release will be at 1:00 p.m. PT / 4:00 p.m. ET and the live conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Dial-in numbers and a webcast are provided; a replay will be available about one hour after the event and archived for approximately one month on the company's investors website.
Neurocrine Biosciences (Nasdaq: NBIX) presented a retrospective real-world claims analysis showing greater treatment persistence with INGREZZA (valbenazine) versus AUSTEDO XR (deutetrabenazine) in adults with tardive dyskinesia.
In matched cohorts (n=1,494 each) over six months, INGREZZA had 55.6% persistence vs 48.1% for AUSTEDO XR (p<0.0001); switching rates were 7.7% vs 11.2% (p=0.0012); median time to discontinuation was >180 days vs 129 days.
Neurocrine (Nasdaq: NBIX) will acquire Soleno for $53.00 per share, valuing the deal at approximately $2.9 billion. The acquisition adds VYKAT XR, which generated $190 million in 2025 revenue (including $92 million in Q4 2025), and its IP expected into the mid-2040s. Post-close, Neurocrine's marketed portfolio will include INGREZZA ($2.51 billion 2025 revenue), CRENESSITY ($301 million 2025 revenue), and VYKAT XR. The tender offer is subject to customary conditions and expected to close within 90 days. Neurocrine will fund the deal with cash on hand and a modest amount of pre-payable debt.
Neurocrine Biosciences (Nasdaq: NBIX) presented the first expert consensus recommendations for screening, diagnosis and treatment of tardive dyskinesia (TD) in long-term care on March 26, 2026. The multidisciplinary Delphi panel endorses routine AIMS screening, quarterly checks for residents on dopamine blockers, and use of VMAT2 inhibitors with tailored selection factors.
A post-hoc KINECT-PRO analysis in adults 65+ shows clinically meaningful patient-reported improvements with once-daily INGREZZA (valbenazine) at Week 24, and the company highlights formulation and dosing features relevant for long-term care residents.
Neurocrine Biosciences (Nasdaq: NBIX) on March 17, 2026 promoted Andrew Ratz, Ph.D., to Chief Technical Operations Officer. Dr. Ratz will lead global technical development, manufacturing and supply chain as the company expands beyond small molecules into biologics and device-based therapies.
Dr. Ratz joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device and brings nearly 30 years of prior executive experience at Eli Lilly. He contributed to the development and registration of more than 25 medicines and holds a B.S. in Chemistry from Indiana University and a Ph.D. in Chemistry from Harvard University.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 4:30 PM ET. The management team will participate and deliver prepared remarks.
A live webcast will be available on the company website under Investors and a replay will be posted about one hour after the event and archived for approximately one month.
BetterInvesting Magazine named Equifax (NYSE: EFX) and Neurocrine Bio (NASDAQ: NBIX) as "Stock to Study" for the May 2026 issue, urging investor research and education rather than buy recommendations.
The Editorial Advisory and Securities Review Committee highlighted fundamental data availability and called both companies worthy of further study for investors using the Stock Selection Guide.
Neurocrine Biosciences (Nasdaq: NBIX) said members of management will present at investor conferences in March 2026, including TD Cowen on March 3 at 11:50 AM ET and Leerink Global on March 9 at 8:40 AM ET.
Live webcasts will stream on the company's investor website with replays posted about one hour after each event and archived for roughly one month.
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 2025 net product sales of $798.3M and full‑year 2025 net product sales of $2.83B, up 29% and 22% YoY. INGREZZA full‑year 2026 net product sales guidance is $2.7–$2.8B. GAAP Q4 net income was $153.7M (EPS $1.48); GAAP FY net income was $478.6M (EPS $4.67). Cash and marketable securities totaled approximately $2.54B at Dec 31, 2025. Company cited increased R&D and SG&A investments to support Phase 3 programs and CRENESSITY launch activities.
Neurocrine Biosciences (Nasdaq: NBIX) initiated a Phase 2 randomized, double-blind, placebo-controlled study of investigational NBI-1065890 in adults with tardive dyskinesia (TD) on Jan 26, 2026. NBI-1065890 is described as a next-generation, selective VMAT2 inhibitor designed for a potentially differentiated, longer-acting profile.
The study will enroll approximately 100 adults and will assess efficacy, safety, and tolerability versus placebo. The primary efficacy endpoint is change from baseline in the AIMS dyskinesia total score (Items 1–7) at Week 8. Neurocrine notes prior FDA approvals for valbenazine in 2017 (tardive dyskinesia) and 2023 (Huntington’s chorea).